{
  "meta": {
    "title": "Heart_Failure_Management_Anti-Arrhythmic_Drugs",
    "url": "https://brainandscalpel.vercel.app/heart-failure-management-anti-arrhythmic-drugs-3290f63d.html",
    "scrapedAt": "2025-11-30T11:19:49.275Z"
  },
  "questions": [
    {
      "id": 1,
      "choices": [
        {
          "id": 1,
          "text": "<p><span style=\"font-size:12.0pt;\">Quinidine: Increased PR and decreased QT interval</span></p>"
        },
        {
          "id": 2,
          "text": "<p><span style=\"font-size:12.0pt;\">Flecainide: Increased QRS interval</span></p>"
        },
        {
          "id": 3,
          "text": "<p><span style=\"font-size:12.0pt;\">Verapamil: Decreased PR interval</span></p>"
        },
        {
          "id": 4,
          "text": "<p><span style=\"font-size:12.0pt;\">Lidocaine: Decreased QRS and PR interval</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following drugs is correctly paired with its ECG effects?</span></p>",
      "unique_key": "DT1179695",
      "question_audio": null,
      "question_video": null,
      "map_id": 1179695,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>Antiarrhythmics are classified based on their electrophysiological effect on the myocardium. </p>\r\n<p>GROUP 1 ANTIARRHYTHMICS (SODIUM CHANNEL BLOCKERS)</p>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/202403084c9ec994-8253-43f3-973e-505eb6001030.jpg\"><br>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/202403081e21009a-d6a9-4a54-a0ed-ae757444bca2.jpg\">\r\n<p><strong>GROUP 2 ANTIARRHYTHMICS (BETA BLOCKERS)</strong></p>\r\n<p><strong>Propranolol</strong> and <strong>esmolol</strong> are prototypic anti-arrhythmic &beta;-blockers. Their mechanism in arrhythmias is primarily <em>cardiac &beta;-adrenoceptor blockade and reduction in cAMP</em>, which results in a modest reduction of both sodium and calcium currents and the suppression of abnormal pacemakers. The AV node is particularly sensitive to &beta;-blockers, and the PR interval is usually prolonged.</p>\r\n<p>Esmolol, a very short-acting &beta; blocker for intravenous administration, is used exclusively in acute arrhythmias. Propranolol and metoprolol are commonly used chronically to prevent arrhythmias in patients who have had a myocardial infarction.</p>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/20240308b68ee4a2-ed1c-4c5d-8073-5e3ba4d5dec5.jpg\"><br>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/202403083dad37b2-d8ed-4235-bca4-fe49470c1398.jpg\">\r\n<p><strong>GROUP 3 ANTIARRHYTHMICS (POTASSIUM IK CHANNEL BLOCKERS)</strong></p>\r\n<ul>\r\n<li>Dofetilide and ibutilide are typical group 3 drugs.</li>\r\n<li>Sotalol is a group 3 antiarrhythmic (not group 2, even if it's a beta blocker)</li>\r\n<li>Amiodarone is useful in most types of arrhythmias and is considered the most efficacious of all anti-arrhythmic drugs. This may be because it has a broad spectrum of action: It blocks sodium, calcium, and potassium channels and &beta;-adrenoceptors.</li>\r\n<li>Dronedarone, an amiodarone analogue, is also approved. Dronedarone does not appear to be as efficacious as amiodarone but may be less toxic.</li>\r\n</ul>\r\n<p><strong>GROUP 4 ANTIARRHYTHMICS (CALCIUM L-TYPE CHANNEL BLOCKERS)</strong></p>\r\n<p>Verapamil is the prototype. Diltiazem is also an effective anti-arrhythmic drug.</p>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/20240308a4bce076-238f-4bce-a27f-ea50a36f34fd.jpg\"><br>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/202403081b3d9ff5-b245-48e1-9165-bb728fb27052.jpg\"><br>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/20240308a3d0dcc1-de11-450a-81f8-642bf49eba2b.jpg\">\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Quinidine (Option A): </strong>As a Class 1A agent, quinidine blocks Na+ and K+channels to slow conduction (&uarr;QRS) and prolong repolarisation (&uarr;QT); it does not decrease the QT interval, and its antimuscarinic action tends to lengthen PR.</p>\r\n<p><strong>Verapamil (Option C): </strong>A Class 4 nondihydropyridine CCB that reduces AV nodal conduction and prolongs the PR interval; it does not decrease PR.</p>\r\n<p><strong>Lidocaine (Option D): </strong>A Class 1B agent with minimal effect on normal ventricular conduction, so it does not significantly change QRS or PR intervals on the ECG.</p>",
      "correct_choice_id": 2,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 2,
      "choices": [
        {
          "id": 11,
          "text": "<p><span style=\"font-size:12.0pt;\">Verapamil</span></p>"
        },
        {
          "id": 12,
          "text": "<p><span style=\"font-size:12.0pt;\">Lidocaine</span></p>"
        },
        {
          "id": 13,
          "text": "<p><span style=\"font-size:12.0pt;\">Flecainide</span></p>"
        },
        {
          "id": 14,
          "text": "<p><span style=\"font-size:12.0pt;\">Quinidine</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">The dotted line represents an action potential following the infusion of the pharmacological agent into cardiomyocytes. The results shown in the graph are most likely caused by which of the following agents?<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250905fbed1b51-8fd1-460a-a3c9-a53294e5d79b.jpg\"></span></p>",
      "unique_key": "DT1179697",
      "question_audio": null,
      "question_video": null,
      "map_id": 1179697,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>The graph shows a ventricular action potential<strong>. The drug changes the duration of the rapid upstroke of the action potential (phase O) without significantly changing the overall duration of the action potential. It shows the effect of class IC antiarrhythmics. It acts by slowly opening voltage-gated sodium channels and decreases the slope of</strong> <strong>phase 0 while still</strong><strong>maintaining the AP duration.</strong> Class IC antiarrhythmics also exhibit use dependence, further decreasing the slope as heart rate increases.</p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/20240308000dfcdd-4407-4bda-b87f-99cca430bc63.jpg\">\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Verapamil (Option A): </strong>A Class 4 L-type Ca<sup>2+</sup> channel blocker that reduces AV nodal conduction and affects the plateau phase in pacemaker cells, not the fast Na<sup>+</sup>- dependent phase 0 in ventricular myocytes.</p>\n<p><strong>Lidocaine (Option B): </strong>A Class 1B agent that slightly reduces phase 0 slope and shortens action-potential duration, which would produce a briefer AP, unlike the unchanged duration observed.</p>\n<p><strong>Quinidine (Option D): </strong>A Class 1A drug that decreases phase 0 slope but prolongs action-potential duration and the QT interval, so it would lengthen rather than maintain the AP duration.</p>",
      "correct_choice_id": 13,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3,
      "choices": [
        {
          "id": 21,
          "text": "<p><span style=\"font-size:12.0pt;\">Verapamil</span></p>"
        },
        {
          "id": 22,
          "text": "<p><span style=\"font-size:12.0pt;\">Propranolol</span></p>"
        },
        {
          "id": 23,
          "text": "<p><span style=\"font-size:12.0pt;\">Flecainide</span></p>"
        },
        {
          "id": 24,
          "text": "<p><span style=\"font-size:12.0pt;\">Amiodarone</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 60-year-old man with COPD comes to you with palpitations and dizziness for 1 week. Her pulse is 75/min and regular, BP is 3.110/80 mm-Hg. An ECG is shown. What is the first line of therapy for her?<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/202403088f6f6bd2-ace4-45eb-b749-2cdff2b02d0a.jpg\"></span></p>",
      "unique_key": "DT1179726",
      "question_audio": null,
      "question_video": null,
      "map_id": 1179726,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>This patient's symptoms and ECG findings <strong>(narrow QRS complexes</strong> with an atrial rate of 240/min in a sawtooth pattern) are most consistent with <strong>atrial flutter</strong>.</p>\r\n<p>A mainstay of the treatment of<strong> stable atrial flutter is to normalise the ventricular heart rate (rate control). </strong></p>\r\n<p>However, consider rhythm control in the following patient groups:</p>\r\n<ul>\r\n<li>Failure of rate control strategy to control symptoms or achieve target heart rate (80bpm)</li>\r\n<li>New-onset Atrial Flutter</li>\r\n<li>Acute illness that precipitated Atrial flutter</li>\r\n<li>Other: tachycardia-induced cardiomyopathy, pregnancy, patient preference, younger patients</li>\r\n</ul>\r\n<p>Drugs used for <strong>rate control include beta-blockers</strong> (e.g., esmolol, propranolol, metoprolol) and non-DHP CCBs (e.g., diltiazem, verapamil). <strong>Verapamil is commonly used as first-line therapy for rate control for atrial flutter, particularly in patients with COPD, as beta blockers are to be avoided in them. (Option B)</strong></p>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/20240308a3bb0360-5eb1-4ef9-8d38-b1d8b8fa2d92.jpg\">\r\n<p>Flecainide (Option C) is a Class 1C antiarrhythmic with selective, state-dependent Na<sup>+</sup> channel block that markedly slows conduction velocity in atrial and ventricular tissue. Primarily used for refractory supraventricular and ventricular arrhythmias due to its proarrhythmic potential and CNS toxicity.</p>\r\n<p><strong>Amiodarone (Option D)</strong> is a broad-spectrum agent (Class III with additional Class I, II, and IV effects) that prolongs action potentials and refractory periods. Reserved for refractory arrhythmias due to toxicities including thyroid dysfunction, pulmonary fibrosis, corneal deposits, optic neuropathy, and rare torsades de pointes.</p>\r\n",
      "correct_choice_id": 21,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 4,
      "choices": [
        {
          "id": 31,
          "text": "<p><span style=\"font-size:12.0pt;\">Adenosine</span></p>"
        },
        {
          "id": 32,
          "text": "<p><span style=\"font-size:12.0pt;\">Digoxin</span></p>"
        },
        {
          "id": 33,
          "text": "<p><span style=\"font-size:12.0pt;\">Lidocaine</span></p>"
        },
        {
          "id": 34,
          "text": "<p><span style=\"font-size:12.0pt;\">Quinidine</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 68-year-old woman comes to the ED with chest pain radiating to the left shoulder. Her ECG reveals ventricular tachycardia with ST-segment elevation. Trop C levels are markedly increased. A diagnosis of myocardial infarction is made. Her arrhythmia will probably be treated initially with</span></p>",
      "unique_key": "DT1179727",
      "question_audio": null,
      "question_video": null,
      "map_id": 1179727,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>Given the clinical scenario of chest pain with <strong>ST-segment elevation and Trop C elevation</strong> suggests myocardial damage, complicated by ventricular tachycardia, a common cause of death in MI patients in the first 24 hours.</p>\n<p>Lidocaine is a Class IB antiarrhythmic of choice for acute ventricular arrhythmias, especially VT, in the setting of myocardial infarction, because it preferentially targets ischemic myocardial cells and has a rapid onset when given intravenously.</p>\n<p><strong>Lidocaine is also useful in digoxin-induced arrhythmias</strong>. After recovery from the acute phase of a myocardial infarction, &beta; blockers are used for 2 years or more to prevent sudden death arrhythmia. Procainamide or amiodarone are used as alternative drugs in this situation.</p>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Adenosine (Option A):</strong> Markedly slows or blocks AV nodal conduction by increasing IK and reducing Ca<sup>2+</sup> current; the drug of choice for AV-nodal reentrant tachycardias due to its low toxicity profile, but <strong>ineffective in ventricular arrhythmias</strong>.</p>\n<p><strong>Digoxin (Option B):</strong> Reduces AV nodal conduction velocity and increases its refractory period to control ventricular rate in atrial flutter/fibrillation; <strong>not indicated for ventricular tachycardia</strong>.</p>\n<p><strong>Quinidine (Option D):</strong> A Class IA agent used for PSVT (AVNRT/AVRT) and ectopic SVTs; side effects include cinchonism (headache, vertigo, tinnitus), cardiac depression, gastrointestinal upset, and immune-mediated thrombocytopenia. It is <strong>less preferred for acute VT</strong> post-MI.</p>",
      "correct_choice_id": 33,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5,
      "choices": [
        {
          "id": 41,
          "text": "<p><span style=\"font-size:12.0pt;\">Adenosine</span></p>"
        },
        {
          "id": 42,
          "text": "<p><span style=\"font-size:12.0pt;\">Amiodarone</span></p>"
        },
        {
          "id": 43,
          "text": "<p><span style=\"font-size:12.0pt;\">Digoxin</span></p>"
        },
        {
          "id": 44,
          "text": "<p><span style=\"font-size:12.0pt;\">Ibutilide</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 32-year-old man comes to the ED, says it feels like \"my heart is racing\", along with palpitations. Blood pressure is 120/80 mm Hg, and pulse is 164/min. ECG is shown below. Treatment is initiated with a medication, which leads to the resolution of the symptom but is accompanied by short-lived flushing, burning in the chest, and shortness of breath. Which of the following medications was used to treat this patient's condition?<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/20240308a36404e4-7638-45a5-8d5f-fa570989bf5b.jpg\"></span></p>",
      "unique_key": "DT1179728",
      "question_audio": null,
      "question_video": null,
      "map_id": 1179728,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>Given a clinical scenario of palpitation and given ECG (Typically narrow QRS complexes, Regular rhythm and P wave is typically not visible), consistent with <strong>paroxysmal supraventricular tachycardia (PSVT</strong>).</p>\n<ul>\n<li><strong>Adenosine is the first-line agent for acute termination of AV nodal-dependent PSVT. </strong>It hyperpolarises AV nodal cells by increasing IK and reducing Ca<sup>2+</sup> current, abruptly blocking conduction and interrupting the reentrant circuit.</li>\n<li>Its extremely rapid onset and very short half-life (&lt;10 seconds) allow for quick restoration of sinus rhythm with minimal prolonged effects.</li>\n<li>Transient adverse effects like flushing, chest burning (bronchospasm), hypotension, and brief high-grade AV block occur due to adenosine's vasodilatory and bronchoconstrictive actions but resolve quickly.</li>\n</ul>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/20240308e57cbcf5-7448-4df8-8888-f2d362e7664a.jpg\">\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Amiodarone (Option B):</strong> A broad-spectrum Class III agent reserved for refractory or life-threatening ventricular and atrial arrhythmias; slow onset and significant long-term toxicities (thyroid, pulmonary, hepatic).</p>\n<p><strong>Digoxin (Option C): </strong>Slows AV nodal conduction by enhancing vagal tone, used for rate control in atrial fibrillation/flutter; onset is too slow for acute PSVT termination and carries the risk of toxicity.</p>\n<p><strong>Ibutilide (Option D):</strong> A Class III drug used for pharmacologic cardioversion of atrial fibrillation/flutter; can induce torsades de pointes and is not indicated for PSVT.</p>",
      "correct_choice_id": 41,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6,
      "choices": [
        {
          "id": 51,
          "text": "<p><span style=\"font-size:12.0pt;\">Blurry yellow vision</span></p>"
        },
        {
          "id": 52,
          "text": "<p><span style=\"font-size:12.0pt;\">Impotence</span></p>"
        },
        {
          "id": 53,
          "text": "<p><span style=\"font-size:12.0pt;\">Prolongation of the AV refractory period</span></p>"
        },
        {
          "id": 54,
          "text": "<p><span style=\"font-size:12.0pt;\">Pulmonary fibrosis</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 70-year-old female presents to the ED with a racing heartbeat. She is subsequently placed on a continuous ECG monitor, and an irregular rhythm is seen. The diagnosis of atrial fibrillation is made. She has started on an amiodarone drip. What side effects should you be aware of when starting amiodarone?</span></p>",
      "unique_key": "DT1179729",
      "question_audio": null,
      "question_video": null,
      "map_id": 1179729,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p><strong>Amiodarone has several well-known side effects, including pulmonary fibrosis, hepatotoxicity, and thyroid imbalances.</strong> For this reason, <strong>pulmonary function tests, liver function tests, and thyroid function tests</strong> should be monitored while taking amiodarone.</p>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/202403089e518b2f-93b9-42b5-8203-c90f88938b01.jpg\"><br>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/20240308eaa19aaf-b854-4b64-ac14-e8729fdaa6b5.jpg\">\r\n<p><strong>Blurry yellow vision (Option A):</strong> A hallmark of digoxin toxicity due to xanthopsia. Amiodarone may cause corneal micro-deposits leading to visual halos, but it does not produce true yellow vision.</p>\r\n<p><strong>Impotence (Option B):</strong> Erectile dysfunction is not associated with amiodarone; drugs more commonly linked to impotence include certain &beta;-blockers and thiazide diuretics. Lupus-like syndromes characterised by malar rash and anti-histone antibodies are seen with hydralazine, procainamide, and isoniazid (SHIP), not with amiodarone.</p>\r\n<p><strong>Prolongation of AV refractory period (Option C):</strong> Characteristic of Class IC agents (e.g., flecainide, propafenone), which potently block Na<sup>+</sup>channels; amiodarone's AV effects stem from its broad, multichannel actions but do not manifest primarily as AV refractory prolongation.</p>",
      "correct_choice_id": 54,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 7,
      "choices": [
        {
          "id": 61,
          "text": "<p><span style=\"font-size:12.0pt;\">EDTA</span></p>"
        },
        {
          "id": 62,
          "text": "<p><span style=\"font-size:12.0pt;\">Nitroprusside</span></p>"
        },
        {
          "id": 63,
          "text": "<p><span style=\"font-size:12.0pt;\">Potassium chloride</span></p>"
        },
        {
          "id": 64,
          "text": "<p><span style=\"font-size:12.0pt;\">Sodium lactate</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 48-year-old male took an overdose and manifested severe acute procainamide toxicity with markedly long QT, which of the following should be given immediately?</span></p>",
      "unique_key": "DT1179730",
      "question_audio": null,
      "question_video": null,
      "map_id": 1179730,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p><strong>Concentrated sodium lactate alkalinises the serum</strong>, increasing the <strong>extracellular sodium gradient</strong> and <strong>enhancing sodium current to overcome procainamide's Na<sup>+</sup> channel blockade, thereby shortening the QT interval.</strong></p>\n<p>Alkalinization also reduces procainamide-receptor binding affinity in cardiac tissue, displacing the drug from Na<sup>+</sup> channels and restoring normal conduction.</p>\n<p>This targeted therapy is preferred in acute Class IA antiarrhythmic overdose; pressor sympathomimetics (e.g., norepinephrine) may be added if hypotension persists after lactate infusion.</p>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>EDTA (Option A):</strong> A chelating agent for heavy-metal poisoning; has no effect on procainamide toxicity or QT prolongation.</p>\n<p><strong>Nitroprusside (Option B):</strong> A powerful arteriolar and venous vasodilator used in hypertensive emergencies; would exacerbate hypotension in this overdose scenario.</p>\n<p><strong>Potassium chloride (Option C):</strong> Raising serum K<sup>+</sup> worsens repolarisation abnormalities and further prolongs the QT interval, increasing the risk of torsades de pointes.</p>",
      "correct_choice_id": 64,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 8,
      "choices": [
        {
          "id": 71,
          "text": "<p><span style=\"font-size:12.0pt;\">Exercise program involving running</span></p>"
        },
        {
          "id": 72,
          "text": "<p><span style=\"font-size:12.0pt;\">Use of calcium channel blockers at high doses</span></p>"
        },
        {
          "id": 73,
          "text": "<p><span style=\"font-size:12.0pt;\">Stopping the use of NSAIDs</span></p>"
        },
        {
          "id": 74,
          "text": "<p><span style=\"font-size:12.0pt;\">Use of beta-blockers at high doses</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 75-year-old man with COPD and chronic heart failure presents to you for follow-up. The patient takes multiple medications for these problems. Which of the following strategies may prove to have additional benefit in the treatment of this patient?</span></p>",
      "unique_key": "DT1179731",
      "question_audio": null,
      "question_video": null,
      "map_id": 1179731,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p><strong>NSAIDs exacerbate heart failure</strong> by <strong>promoting sodium and water retention</strong>, blunting diuretic efficacy, and <strong>reducing renal perfusion via prostaglandin inhibition</strong>. Discontinuation improves volume status and renal function.</p>\r\n<p>Chronic HF is typically managed by</p>\r\n<ul>\r\n<li>A reduction in physical activity</li>\r\n<li>Low dietary intake of sodium (&lt;1500 mg/d)</li>\r\n<li>Treatment of comorbid conditions</li>\r\n<li>Judicious use of diuretics, inhibitors of the renin-angiotensin system, and inotropic agents.</li>\r\n</ul>\r\n<p><strong>Drugs that may precipitate or exacerbate HF, such as NSAIDs, alcohol, calcium channel blockers, high-dose beta-blockers, and some antiarrhythmic drugs, should be avoided if possible.</strong></p>\r\n<p>Patients with HF complain of dyspnea on exertion, orthopnea, paroxysmal nocturnal dyspnea, fatigue, and dependent oedema.</p>\r\n<ol>\r\n<li>Vigorous exercise in this deconditioned patient may worsen heart function. <strong>(Option A)</strong></li>\r\n<li>Use of calcium channel blockers at high doses can worsen heart failure. <strong>(Option B)</strong></li>\r\n<li>Use of beta-blockers at high doses can worsen heart failure. <strong>(Option D)</strong></li>\r\n</ol>",
      "correct_choice_id": 73,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 9,
      "choices": [
        {
          "id": 81,
          "text": "<p><span style=\"font-size:12.0pt;\">Vascular resistance</span></p>"
        },
        {
          "id": 82,
          "text": "<p><span style=\"font-size:12.0pt;\">Venous tone</span></p>"
        },
        {
          "id": 83,
          "text": "<p><span style=\"font-size:12.0pt;\">Venous distension of the jugular vein</span></p>"
        },
        {
          "id": 84,
          "text": "<p><span style=\"font-size:12.0pt;\">Exercise tolerance</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 62-year-old man who is a chronic smoker with chronic congestive heart failure presents for follow-up. He is currently taking captopril and hydrochlorothiazide. Which of the following changes would be increased as a result of this therapy?</span></p>",
      "unique_key": "DT1179732",
      "question_audio": null,
      "question_video": null,
      "map_id": 1179732,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p><strong>Captopril (an ACE inhibitor) and hydrochlorothiazide reduce afterload </strong>(via decreased vascular resistance) <strong>and preload</strong> (via venodilation and diuresis), <strong>which together increase cardiac output and alleviate congestive symptoms.</strong></p>\r\n<p>ACE inhibitors and thiazides may improve the clinical signs of heart failure. As such, patients may have some improvement in how they feel and may be able to ambulate without as much exertion.</p>\r\n<p><strong>ACE inhibitors decrease vascular resistance, venous tone, and blood pressure</strong>. These drugs reduce preload and afterload, resulting in an increased cardiac output. ACE inhibitors also blunt the usual angiotensin II-mediated increase in epinephrine and aldosterone seen in HF.</p>\r\n<p>ACE inhibitors improve clinical signs and symptoms in patients also receiving thiazide or loop diuretics and/or digoxin.</p>\r\n<ul>\r\n<li>Vascular resistance will decrease in patients taking an ACE inhibitor. <strong>(Option A)</strong></li>\r\n<li>Venous tone will decrease in patients taking an ACE inhibitor. <strong>(Option B)</strong></li>\r\n<li>Jugular venous distension is a clinical sign that may improve with an ACE inhibitor. <strong>(Option C)</strong></li>\r\n</ul>",
      "correct_choice_id": 84,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 10,
      "choices": [
        {
          "id": 91,
          "text": "<p><span style=\"font-size:12.0pt;\">Bicarbonate </span></p>"
        },
        {
          "id": 92,
          "text": "<p><span style=\"font-size:12.0pt;\">Chloride </span></p>"
        },
        {
          "id": 93,
          "text": "<p><span style=\"font-size:12.0pt;\">Sodium</span></p>"
        },
        {
          "id": 94,
          "text": "<p><span style=\"font-size:12.0pt;\">Potassium </span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 51-year-old man with congestive heart failure and hypertension comes for follow-up. His current medications include digoxin and a calcium channel blocker. Serum electrolytes and a complete blood count are drawn. Which of the following blood indicators is most important to follow in this patient?</span></p>",
      "unique_key": "DT1179735",
      "question_audio": null,
      "question_video": null,
      "map_id": 1179735,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p><strong>Digoxin toxicity is one of the most commonly encountered adverse drug reactions.</strong> Side effects often can be managed by discontinuing cardiac glycoside therapy, determining serum <strong>potassium levels </strong>(decreased K+ increases the potential for cardiotoxicity), and, if indicated, giving potassium supplements.</p>\n<p><strong>Treatment of digitalis toxicity includes several steps, as follows.</strong></p>\n<ul>\n<li><strong>Correction of potassium or magnesium deficiency </strong>- Correction of potassium deficiency (caused, eg, by diuretic use) is useful in chronic digitalis intoxication. Mild toxicity may often be managed by omitting 1 or 2 doses of digitalis and giving oral or parenteral K+ supplements. Severe acute intoxication (as in suicidal overdoses) usually causes marked hyperkalemia and should not be treated with supplemental potassium.</li>\n<li><strong>Anti-arrhythmic drugs</strong> - Anti-arrhythmic drugs may be useful if increased automaticity is prominent and does not respond to normalisation of serum potassium. Agents that do not severely impair cardiac contractility (eg, lidocaine or phenytoin) are in favour, but drugs such as propranolol have also been used successfully. Severe acute digitalis overdose usually causes marked inhibition of all cardiac pacemakers, and an electronic pacemaker may be required. Anti-arrhythmic drugs are dangerous in such patients.</li>\n<li><strong>Digoxin antibodies</strong> - Digoxin antibodies (Fab fragments; Digibind ) are extremely effective and should always be used if other therapies appear to be failing. They are effective for poisoning with several cardiac glycosides in addition to digoxin and may save patients who would otherwise die.</li>\n</ul>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Bicarbonate (Option A):</strong> Acid-base status can influence electrolyte shifts, but is not directly implicated in digoxin toxicity management.</p>\n<p><strong>Chloride (Option B):</strong> Serum Cl<sup>-</sup> rarely affects digoxin pharmacodynamics or toxicity risk.</p>\n<p><strong>Sodium (Option C):</strong> While Na<sup>+</sup> gradients drive digoxin's mechanism, daily serum sodium fluctuations are less predictive of toxicity than K<sup>+</sup> levels.</p>",
      "correct_choice_id": 94,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 11,
      "choices": [
        {
          "id": 101,
          "text": "<p><span style=\"font-size:12.0pt;\">Increased parasympathetic discharge</span></p>"
        },
        {
          "id": 102,
          "text": "<p><span style=\"font-size:12.0pt;\">Increased intracellular calcium</span></p>"
        },
        {
          "id": 103,
          "text": "<p><span style=\"font-size:12.0pt;\">Decreased intracellular ATP</span></p>"
        },
        {
          "id": 104,
          "text": "<p><span style=\"font-size:12.0pt;\">Increased extracellular potassium</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 48-year-old man presents to the emergency department with an arrhythmia. He has been receiving digoxin for 4 weeks. Which one of the following is most likely to contribute to the arrhythmogenic effect of digoxin?</span></p>",
      "unique_key": "DT1179738",
      "question_audio": null,
      "question_video": null,
      "map_id": 1179738,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p><strong>Chronic digoxin intoxication leads to Na<sup>+</sup>/K<sup>+</sup>-ATPase inhibition</strong>, causing a modest rise in intracellular Na<sup>+</sup> that impairs the Na<sup>+</sup>/Ca<sup>2+</sup> exchanger (NCX), resulting in Ca<sup>2+</sup> overload within cardiomyocytes.</p>\n<p>This elevated intracellular Ca<sup>2+</sup> is sequestered in the sarcoplasmic reticulum and can precipitate delayed afterdepolarizations and abnormal automaticity, directly triggering arrhythmias.</p>\n<p>Calcium overload underlies the extension of digoxin's therapeutic inotropy into toxic arrhythmogenesis, particularly in settings of hypokalemia or renal impairment.</p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/202403081cab8640-e314-414e-a309-fc7e79e3613b.jpg\">\n<p>Various types of arrhythmias can manifest depending on the site of predominance.</p>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Increased parasympathetic discharge (Option A):</strong> Digoxin does enhance vagal tone, slowing AV nodal conduction, but this effect is not proarrhythmic; it actually can help control ventricular rate in atrial arrhythmias.</p>\n<p><strong>Decreased intracellular ATP (Option C):</strong> Inhibition of Na<sup>+</sup>/K<sup>+</sup>- ATPase by digoxin does not reduce ATP levels; rather, increased Ca<span style=\"font-size: xx-small;\"><sup>2+</sup> </span> cycling can actually elevate energy demand and ATP turnover.</p>\n<p><strong>Increased extracellular potassium (Option D):</strong> Hyperkalemia antagonises digoxin binding to its receptor, reducing toxicity; thus, higher extracellular K<sup>+</sup> is protective against arrhythmias.</p>",
      "correct_choice_id": 102,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 12,
      "choices": [
        {
          "id": 111,
          "text": "<p><span style=\"font-size:12.0pt;\">Digoxin</span></p>"
        },
        {
          "id": 112,
          "text": "<p><span style=\"font-size:12.0pt;\">Furosemide </span></p>"
        },
        {
          "id": 113,
          "text": "<p><span style=\"font-size:12.0pt;\">Propranolol </span></p>"
        },
        {
          "id": 114,
          "text": "<p><span style=\"font-size:12.0pt;\">Spironolactone</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 62-year-old woman develops acute severe heart failure with marked pulmonary oedema, but no evidence of peripheral oedema. She has been admitted to the ICU for LVMI. Which one of the following drugs would be most useful?</span></p>",
      "unique_key": "DT1179741",
      "question_audio": null,
      "question_video": null,
      "map_id": 1179741,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p><strong>Acute severe congestive failure with pulmonary oedema often requires a vasodilator</strong> that reduces intravascular pressures in the lungs.<strong> Furosemide has such vasodilating actions in the context of acute failure in addition to its diuretic effect.</strong> Pulmonary oedema also involves a shift of fluid from the intravascular compartment to the lungs.</p>\r\n<p>Current clinical evidence suggests that acute heart failure should be treated with a loop diuretic; if severe, a prompt-acting positive inotropic agent such as a &beta; agonist or phosphodiesterase inhibitor, and vasodilators should be used as required to optimise filling pressures and blood pressure.</p>\r\n<p><strong>Chronic failure is best treated with diuretics </strong>(often a loop agent plus spironolactone) plus an <strong>ACE inhibitor and, if tolerated, a &beta; blocker.</strong> <strong>Digitalis may be helpful if systolic dysfunction is prominent</strong>. <strong>Nesiritide,</strong> a recombinant form of <strong>brain natriuretic peptide (BNP)</strong>, has <strong>vasodilating and diuretic properties</strong> and has been heavily promoted for <strong>use in acute failure. </strong></p>\r\n<p>A newer combination drug, <strong>sacubitril/valsartan</strong>, combines the actions of increased endogenous BNP with those of the angiotensin receptor blocker valsartan.</p>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Digoxin (Option A):</strong> Provides symptomatic relief and modest hospitalisation reduction but does not improve survival in chronic heart failure.</p>\r\n<p><strong>Furosemide (Option B):</strong> A loop diuretic that relieves congestion but has no demonstrated mortality benefit.</p>\r\n<p><strong>Nitroprusside (Option C): </strong>An acute vasodilator used in hypertensive emergencies and acute decompensation; it does not alter long-term survival.</p>",
      "correct_choice_id": 112,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 13,
      "choices": [
        {
          "id": 121,
          "text": "<p><span style=\"font-size:12.0pt;\">Digoxin</span></p>"
        },
        {
          "id": 122,
          "text": "<p><span style=\"font-size:12.0pt;\">Furosemide </span></p>"
        },
        {
          "id": 123,
          "text": "<p><span style=\"font-size:12.0pt;\">Nitroprusside </span></p>"
        },
        {
          "id": 124,
          "text": "<p><span style=\"font-size:12.0pt;\">Spironolactone</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 77-year-old man has chronic heart failure. Which one of the following drugs has been shown to reduce mortality?</span></p>",
      "unique_key": "DT1179749",
      "question_audio": null,
      "question_video": null,
      "map_id": 1179749,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>Clinical trials (e.g., RALES) have demonstrated that adding the aldosterone antagonist spironolactone to standard therapy significantly reduces mortality and hospitalisations in patients with severe chronic heart failure.</p>\r\n<p>Spironolactone blocks detrimental aldosterone effects (myocardial fibrosis, vascular remodelling, and sodium retention), providing long-term survival benefits beyond symptomatic relief.</p>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/20240308964a4d34-2617-4078-98af-2b6661540a22.jpg\">\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Digoxin (Option A):</strong> Improves symptoms and reduces hospitalisations but <strong>does not</strong> confer a mortality benefit in chronic heart failure.</p>\r\n<p><strong>Furosemide (Option B):</strong> A loop diuretic that alleviates volume overload and improves symptoms, yet has <strong>no demonstrated</strong> impact on long-term survival.</p>\r\n<p><strong>Nitroprusside (Option C):</strong> An acute vasodilator used for decompensated heart failure and hypertensive emergencies; it provides symptomatic relief but <strong>does not</strong> improve chronic survival.</p>",
      "correct_choice_id": 124,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 14,
      "choices": [
        {
          "id": 131,
          "text": "<p><span style=\"font-size:12.0pt;\">Digi bind</span></p>"
        },
        {
          "id": 132,
          "text": "<p><span style=\"font-size:12.0pt;\">Lidocaine infusion</span></p>"
        },
        {
          "id": 133,
          "text": "<p><span style=\"font-size:12.0pt;\">Phenytoin  </span></p>"
        },
        {
          "id": 134,
          "text": "<p><span style=\"font-size:12.0pt;\">Potassium </span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 6-year-old child collapses while playing. He has sinus arrest and a ventricular rate of 35 bpm. An empty bottle of his uncle's digoxin was found where he was playing. Which of the following is the drug of choice in treating a severe overdose of digoxin?</span></p>",
      "unique_key": "DT1179752",
      "question_audio": null,
      "question_video": null,
      "map_id": 1179752,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p><strong>The drug of choice in severe, massive overdose with any cardiac glycoside is digoxin antibody</strong>,<strong> DigiBind</strong>. The other drugs listed are used in moderate overdosage associated with increased automaticity.</p>\r\n<p>Treatment of digitalis toxicity includes several steps, as follows.</p>\r\n<ul>\r\n<li><strong>Correction of potassium or magnesium deficiency</strong>- Correction of potassium deficiency (caused, eg, by diuretic use) is useful in chronic digitalis intoxication. Mild toxicity may often be managed by omitting 1 or 2 doses of digitalis and giving oral or parenteral K+ supplements. Severe acute intoxication (as in suicidal overdoses) usually causes marked hyperkalemia and should not be treated with supplemental potassium.</li>\r\n<li><strong>Anti-arrhythmic drugs</strong>-Anti-arrhythmic drugs may be useful if increased automaticity is prominent and does not respond to normalisation of serum potassium. Agents that do not severely impair cardiac contractility (eg, lidocaine or phenytoin) are favoured, but drugs such as propranolol have also been used successfully. Severe acute digitalis overdose usually causes marked inhibition of all cardiac pacemakers, and an electronic pacemaker may be required. Anti-arrhythmic drugs are dangerous in such patients.</li>\r\n<li><strong>Digoxin antibodies</strong>-Digoxin antibodies (Fab fragments; Digi bind) are extremely effective and should always be used if other therapies appear to be failing. They are effective for poisoning with several cardiac glycosides in addition to digoxin and may save patients who would otherwise die.</li>\r\n</ul>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Lidocaine infusion (Option B): </strong>A Class IB antiarrhythmic effective for treating ventricular arrhythmias in moderate digitalis toxicity, but it does not remove the toxin itself.</p>\r\n<p><strong>Phenytoin (Option C): </strong>Can suppress digitalis-induced ventricular ectopy by stabilising membrane excitability, yet it is an adjunct for arrhythmia control, not the definitive antidote.</p>\r\n<p><strong>Potassium (Option D): </strong>Oral or IV K<sup>+</sup>corrects hypokalemia in chronic toxicity but is contraindicated in severe acute overdose, where hyperkalemia is common and would worsen outcomes.</p>",
      "correct_choice_id": 131,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 15,
      "choices": [
        {
          "id": 141,
          "text": "<p><span style=\"font-size:12.0pt;\">Prostacyclin</span></p>"
        },
        {
          "id": 142,
          "text": "<p><span style=\"font-size:12.0pt;\">Aldosterone</span></p>"
        },
        {
          "id": 143,
          "text": "<p><span style=\"font-size:12.0pt;\">Antidiuretic hormone</span></p>"
        },
        {
          "id": 144,
          "text": "<p><span style=\"font-size:12.0pt;\">Brain natriuretic peptide</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 78-year-old man with systolic heart failure comes to you for worsening shortness of breath at rest for 3 days. As a part of treatment, he is given a derivative of a hormone that acts by altering guanylate cyclase activity. This drug has been found to reduce pulmonary capillary wedge pressure and causes systemic hypotension as an adverse effect. The drug is most likely a derivative of which of the following hormones?</span></p>",
      "unique_key": "DT1179754",
      "question_audio": null,
      "question_video": null,
      "map_id": 1179754,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>This patient's acute decompensated CHF was treated with <strong>nesiritide, a recombinant BNP derivative.</strong> Although rarely used today due to cost and hypotension risk, nesiritide remains an option for refractory acute heart failure.</p>\r\n<p><strong>BNP analogues bind natriuretic peptide receptor-A</strong> (a membrane guanylate cyclase), <strong>increasing cGMP in vascular smooth muscle to produce rapid venous and arterial vasodilation</strong>, thereby lowering PCWP and improving pulmonary congestion.</p>\r\n<p>The systemic hypotension observed is a predictable consequence of potent cGMP-mediated vasodilation. Blood pressure must be monitored closely during infusion.</p>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Prostacyclin (Option A):</strong> A PGI<sub><span style=\"font-size: xx-small;\">2</span></sub> analogue that causes vasodilation and inhibits platelet aggregation via a GPCR-cAMP pathway; used in pulmonary arterial hypertension but does <strong>not</strong> act through guanylate cyclase nor reduce PCWP in acute CHF.</p>\r\n<p><strong>Aldosterone (Option B):</strong> Signals via nuclear receptors to promote sodium retention and fibrosis; aldosterone antagonists (spironolactone/eplerenone) improve chronic CHF survival but are <strong>not</strong> used acutely and <strong>do not modulate</strong> guanylate cyclase.</p>\r\n<p><strong>Antidiuretic hormone (Option C):</strong> Acts on V1 (PLC) and V2 (cAMP) receptors to regulate water balance and vasoconstriction; vasopressin antagonists (e.g., tolvaptan) affect volume but do <strong>not</strong> engage guanylate cyclase for vasodilation.</p>",
      "correct_choice_id": 144,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 16,
      "choices": [
        {
          "id": 151,
          "text": "<p><span style=\"font-size:12.0pt;\">Ibuprofen</span></p>"
        },
        {
          "id": 152,
          "text": "<p><span style=\"font-size:12.0pt;\">Pioglitazone</span></p>"
        },
        {
          "id": 153,
          "text": "<p><span style=\"font-size:12.0pt;\">Verapamil</span></p>"
        },
        {
          "id": 154,
          "text": "<p><span style=\"font-size:12.0pt;\">Amlodipine</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 65-year-old woman with chronic CHF. All of the following drugs should be avoided except?</span></p>",
      "unique_key": "DT1179756",
      "question_audio": null,
      "question_video": null,
      "map_id": 1179756,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p><strong>Amlodipine</strong>, a dihydropyridine calcium-channel blocker, causes arterial vasodilation with minimal negative inotropic effect, and <strong>does not significantly worsen left ventricular function in CHF.</strong></p>\r\n<p>Unlike nondihydropyridines, dihydropyridines have little impact on cardiac contractility or conduction, making amlodipine the only safe CCB in decompensated or chronic heart failure.</p>\r\n<p>Trials have shown that amlodipine does not increase mortality or hospitalisation rates in CHF when used appropriately for comorbid hypertension or angina.</p>\r\n<p><strong>Drugs that may worsen CHF</strong></p>\r\n<ul>\r\n<li>Most antiarrhythmic agents</li>\r\n<li>Calcium channel blockers (except amlodipine) <strong>(Option C)</strong></li>\r\n<li>NSAIDs <strong>(Option A)</strong></li>\r\n<li>Thiazolidinediones (e.g., pioglitazone) <strong>(Option B)</strong></li>\r\n<li>Inhalation anesthetics</li>\r\n<li>Cautious selection of antidepressants due to numerous interactions and adverse effects when used with HF drugs (SSRIs may be used judiciously)</li>\r\n</ul>",
      "correct_choice_id": 154,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 17,
      "choices": [
        {
          "id": 161,
          "text": "<p><span style=\"font-size:12.0pt;\">Enalapril</span></p>"
        },
        {
          "id": 162,
          "text": "<p><span style=\"font-size:12.0pt;\">Atorvastatin</span></p>"
        },
        {
          "id": 163,
          "text": "<p><span style=\"font-size:12.0pt;\">Abciximab</span></p>"
        },
        {
          "id": 164,
          "text": "<p><span style=\"font-size:12.0pt;\">Nifedipine</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 78-year-old woman presents with increasing shortness of breath for 3 months. She underwent an emergency PCI for myocardial infarction 12 months ago. At the time of discharge, EDV was 300 mL, and ejection fraction was 58%. She admits to rarely taking her medication as she usually feels well and has no symptoms. Current Echocardiography shows left ventricular dilation and an end-diastolic volume of 390 mL; Ejection fraction is 35%. Which of the following is most likely to have prevented this patient's worsening of ventricular function?</span></p>",
      "unique_key": "DT1179758",
      "question_audio": null,
      "question_video": null,
      "map_id": 1179758,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>This patient's progressive dyspnea, reduced EF, and LV dilation reflect unhindered post-MI cardiac remodelling due to lack of neurohormonal blockade.</p>\r\n<p>Enalapril, an ACE inhibitor, blocks angiotensin II formation, reducing preload and afterload, which slows the rate of LV dilation and limits adverse remodelling after MI.</p>\r\n<p>Early and sustained ACE-inhibitor therapy post-MI preserves ventricular geometry, maintains EF, and improves long-term clinical outcomes.</p>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Atorvastatin (Option B):</strong> Lowers LDL and stabilises plaques but does not directly inhibit post-MI ventricular remodelling.</p>\r\n<p><strong>Abciximab (Option C):</strong> A glycoprotein IIb/IIIa inhibitor used acutely during PCI to prevent thrombosis; it does not affect chronic remodelling.</p>\r\n<p><strong>Nifedipine (Option D):</strong> A dihydropyridine CCB that can worsen systolic function and has no role in preventing post-MI remodelling.</p>",
      "correct_choice_id": 161,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 18,
      "choices": [
        {
          "id": 171,
          "text": "<p><span style=\"font-size:12.0pt;\">1-A 2-C 3-D 4-B</span></p>"
        },
        {
          "id": 172,
          "text": "<p><span style=\"font-size:12.0pt;\">1-C 2-A 3-D 4-B</span></p>"
        },
        {
          "id": 173,
          "text": "<p><span style=\"font-size:12.0pt;\">1-C 2-D 3-A 4-B</span></p>"
        },
        {
          "id": 174,
          "text": "<p><span style=\"font-size:12.0pt;\">1-D 2-A 3-C 4-B</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Match the following mechanism with its drug used in heart failure.<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/202403083d2c811e-cf88-4a6f-b0f2-823923bab17c.jpg\"></span></p>",
      "unique_key": "DT1179764",
      "question_audio": null,
      "question_video": null,
      "map_id": 1179764,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation for answer:</strong></p>\n<ul>\n<li><strong>Captopril, </strong>as an ACE inhibitor, lowers angiotensin II, <strong>reducing both preload and afterload </strong>and <strong>preventing post-MI ventricular remodelling.</strong></li>\n<li><strong>Carvedilol's</strong> &beta;-blockade plus &alpha;<sub>1</sub>-blockade <strong>decreases afterload and attenuates neurohormonal remodelling.</strong></li>\n<li>By antagonising aldosterone, <strong>spironolactone</strong> <strong>reduces sodium/water retention (preload) and, indirectly, vascular resistance (afterload).</strong></li>\n<li><strong>Milrinone </strong>is A PDE-3 inhibitor that elevates cAMP to<strong> increase contractility</strong> while dilating arterioles and veins.</li>\n</ul>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/20240308880cebf9-37f0-4627-a41a-26c190bb002a.jpg\">\n<p><strong>Other drugs for heart failure, with their mechanism</strong></p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/202403086cfea968-36e0-4db3-b396-f6fc5e9d11f2.jpg\">",
      "correct_choice_id": 172,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19,
      "choices": [
        {
          "id": 181,
          "text": "<p><span style=\"font-size:12.0pt;\">It is a PDE-3 inhibitor and acts by decreasing cAMP in myocardium and peripheral vessels.</span></p>"
        },
        {
          "id": 182,
          "text": "<p><span style=\"font-size:12.0pt;\">It can be used in cardiac failure with cardiogenic shock</span></p>"
        },
        {
          "id": 183,
          "text": "<p><span style=\"font-size:12.0pt;\">It should not be used long-term as it may cause ventricular arrhythmia.</span></p>"
        },
        {
          "id": 184,
          "text": "<p><span style=\"font-size:12.0pt;\">It can &uarr; inotropy and &uarr; chronotropy effects in the myocardium as well as vasodilation.</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 72-year-old woman admitted to the ICU for a cardiac condition started on amrinone. Which of the following is NOT true about the drug?</span></p>",
      "unique_key": "DT1179766",
      "question_audio": null,
      "question_video": null,
      "map_id": 1179766,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<ul>\r\n<li>Amrinone is a phosphodiesterase-3 inhibitor that increases intracellular cAMP in cardiac and vascular smooth muscle cells, enhancing contractility and causing vasodilation-so statement A is false.</li>\r\n<li>By preventing cAMP breakdown, it augments protein kinase A activity, raising calcium availability in myocytes for a positive inotropic and chronotropic effect and relaxing vascular smooth muscle to reduce afterload and preload.</li>\r\n<li>Amrinone's combined inotropic and vasodilatory properties make it useful in acute heart failure complicated by cardiogenic shock to improve cardiac output and perfusion. <strong>(Option B)</strong></li>\r\n<li>Chronic use is limited by an increased risk of ventricular arrhythmias and thrombocytopenia; therefore, it is reserved for short-term support. <strong>(Option C)</strong></li>\r\n<li>The rise in cAMP enhances calcium influx in cardiomyocytes (&uarr; inotropy, &uarr; chronotropy) and induces arterial and venous dilation, lowering filling pressures. <strong>(Option D)</strong></li>\r\n</ul>\r\n<p>Salient feature of PDE-3 inhibitor</p>\r\n<img class=\"w-100\" style=\"height:auto;display:block;vertical-align: middle;border:0; \"src=\"https://d1mobye7msb5bl.cloudfront.net/2NewQBImages/bd277f75-a4c1-40da-bf81-71531d57891a.png\">",
      "correct_choice_id": 181,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20,
      "choices": [
        {
          "id": 191,
          "text": "<p><span style=\"font-size:12.0pt;\">IV MgSO4</span></p>"
        },
        {
          "id": 192,
          "text": "<p><span style=\"font-size:12.0pt;\">IV lidocaine</span></p>"
        },
        {
          "id": 193,
          "text": "<p><span style=\"font-size:12.0pt;\">IV Esmolol</span></p>"
        },
        {
          "id": 194,
          "text": "<p><span style=\"font-size:12.0pt;\">Increase the dose of amiodarone</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 56-year-old man presents with a complaint of syncope. He had a sudden onset of palpitations followed by loss of consciousness while working in the office. Medications include lisinopril, metformin, and amiodarone. He has been taking itraconazole for 3 days. He's stable now. ECG shown below. What is the next line of treatment for his condition?<br><img class=\"w-100\" style=\"height:auto;display:block;vertical-align: middle;border:0; \"src=\"https://d1mobye7msb5bl.cloudfront.net/2NewQBImages/69094ce6-5d56-4e17-ab22-91cbae1a7964.png\"></span></p>",
      "unique_key": "DT1179770",
      "question_audio": null,
      "question_video": null,
      "map_id": 1179770,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p><strong>Polymorphic ventricular tachycardia with cyclic alteration of the QRS axis</strong> (sinusoidal waveform) is referred to as <strong>torsades de pointes and can progress to life-threatening ventricular fibrillation. </strong></p>\r\n<p>Treatment consists of administering <strong>magnesium sulphate 2g IV</strong>, repeated as needed.</p>\r\n<p>Acquired prolongation of the QT interval can be caused by certain medications (e.g., amiodarone, methadone, and ondansetron) or electrolyte imbalances (e.g., hypokalemia, hypomagnesemia, and hypocalcemia). This patient's history of amiodarone and itraconazole therapy makes drug-induced QT prolongation that progressed to torsades de pointes the most likely cause of his syncope.</p>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/2024030871dfe581-7d68-4149-b69b-de0d806fda1d.jpg\">\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>IV lidocaine (Option B): </strong>A Class IB agent effective for ischemic ventricular tachycardia but ineffective against torsades, which stems from repolarisation abnormalities rather than reentry.</p>\r\n<p><strong>IV esmolol (Option C): </strong>A &beta;-blocker that may help congenital long QT syndromes but is not first-line in drug-induced torsades de pointes.</p>\r\n<p><strong>Increase dose of amiodarone (Option D):</strong> Would worsen QT prolongation and exacerbate torsades, making it contraindicated.</p>",
      "correct_choice_id": 191,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 21,
      "choices": [
        {
          "id": 201,
          "text": "<p><span style=\"font-size:12.0pt;\">Prolonged QT interval</span></p>"
        },
        {
          "id": 202,
          "text": "<p><span style=\"font-size:12.0pt;\">Shortened PR interval</span></p>"
        },
        {
          "id": 203,
          "text": "<p><span style=\"font-size:12.0pt;\">Prolonged QRS complex</span></p>"
        },
        {
          "id": 204,
          "text": "<p><span style=\"font-size:12.0pt;\">Decreased maximal heart rate</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 56-year-old woman comes to you for a follow-up. She feels well and wants to stop her only current medication, flecainide. Which of the following ECG changes is most likely to be seen on cardiac stress testing in this patient?</span></p>",
      "unique_key": "DT1179772",
      "question_audio": null,
      "question_video": null,
      "map_id": 1179772,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p><strong>Flecainide is a class IC antiarrhythmic used in patients with paroxysmal supraventricular arrhythmias and no other structural heart disease.</strong> It blocks fast sodium channels responsible for phase 0 of the myocardial action potential (rapid upstroke and depolarisation).</p>\r\n<p>The effect is an action potential with decreased slope and amplitude, which prolongs the spread of depolarisation to neighbouring cells, slowing conduction through the myocardium. Since phase 0 for ventricular myocytes corresponds to the QRS complex on ECG, <strong>flecainide prolongs the QRS complex. </strong></p>\r\n<p>This particular effect of class I antiarrhythmic drugs, especially of class IC antiarrhythmic drugs, is use/state-dependent, i.e., it increases with the heart rate (e.g., during cardiac stress testing), as more sodium channels are recruited for cardiac contraction.</p>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Prolongation of the QTc interval (Option A) </strong>is a possible ECG change seen on cardiac stress testing in patients taking class IA and class III antiarrhythmic drugs, which block potassium channels, resulting in a prolonged repolarisation phase of the cardiac action potential.</p>\r\n<p><strong>Shortened PR interval (Option B): </strong>Class I antiarrhythmic drugs act by blocking the sodium channels in cardiomyocytes, which results in <strong>prolongation of the PR interval, not shortening.</strong> In patients taking flecainide, first- and second-degree AV block may be seen on cardiac stress testing.</p>\r\n<p><strong>Decreased maximal heart rate (Option D)</strong> is an ECG change typically seen on cardiac stress testing in patients taking beta blockers.</p>",
      "correct_choice_id": 203,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 22,
      "choices": [
        {
          "id": 211,
          "text": "<p><span style=\"font-size:12.0pt;\">Lidocaine</span></p>"
        },
        {
          "id": 212,
          "text": "<p><span style=\"font-size:12.0pt;\">Verapamil</span></p>"
        },
        {
          "id": 213,
          "text": "<p><span style=\"font-size:12.0pt;\">Carvedilol</span></p>"
        },
        {
          "id": 214,
          "text": "<p><span style=\"font-size:12.0pt;\">Quinidine</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following drugs prolongs the QRS and QT intervals?</span></p>",
      "unique_key": "DT1179773",
      "question_audio": null,
      "question_video": null,
      "map_id": 1179773,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p><strong>Quinidine is a Class IA antiarrhythmic </strong>that blocks fast Na channels (phase 0) and also inhibits K<sup>+</sup> channels (phase 3), slowing depolarisation and delaying repolarisation, <strong>thereby widening the QRS and prolonging the QT interval.</strong></p>\n<p>The \"use-dependence\"of quinidine means its effects intensify at higher heart rates, increasing both QRS duration and QT prolongation, which can predispose to torsades de pointes.</p>\n<p>Clinically, monitoring both intervals is essential when initiating quinidine to balance antiarrhythmic efficacy against proarrhythmic risk.</p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/202403088d963a72-b513-48b6-ab4d-329f8ae47e2b.jpg\">\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Lidocaine (Option A):</strong> A Class IB agent that shortens action-potential duration and has minimal effect on QRS or QT intervals.</p>\n<p><strong>Verapamil (Option B): </strong>A Class IV calcium-channel blocker that prolongs the PR interval but does not significantly affect QRS or QT.</p>\n<p><strong>Carvedilol (Option C):</strong> A nonselective &beta;-blocker with &alpha;<sub>1</sub>-blockade that can slow heart rate and AV conduction but does not prolong QRS or QT intervals.</p>",
      "correct_choice_id": 214,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 23,
      "choices": [
        {
          "id": 221,
          "text": "<p><span style=\"font-size:12.0pt;\">Potassium supplementation</span></p>"
        },
        {
          "id": 222,
          "text": "<p><span style=\"font-size:12.0pt;\">Propranolol</span></p>"
        },
        {
          "id": 223,
          "text": "<p><span style=\"font-size:12.0pt;\">Atropine</span></p>"
        },
        {
          "id": 224,
          "text": "<p><span style=\"font-size:12.0pt;\">Digibind</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 78-year-old man is presented with diarrhoea, palpitations, blurry vision, and headache for 3 days. Current medications include warfarin, metoprolol, digoxin, ramipril, insulin, and spironolactone. The abdomen is soft with diffuse, mild tenderness to palpation. An ECG shows a second-degree AV block. Next line of management?</span></p>",
      "unique_key": "DT1179775",
      "question_audio": null,
      "question_video": null,
      "map_id": 1179775,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p><strong>The combination of gastrointestinal symptoms, visual disturbances, headache, and new AV block in a patient on digoxin with potential renal impairment strongly suggests digoxin toxicity.</strong></p>\r\n<p>Digoxin-specific antibody fragments (Digibind) rapidly bind circulating digoxin, reversing Na<sup>+</sup>/K<sup>+</sup>-ATPase inhibition and resolving life-threatening arrhythmias and hyperkalemia.</p>\r\n<p>In severe or life-threatening digitalis overdose, manifested by high-grade AV block or hyperkalemia. Fab fragments are the definitive therapy and should be administered without delay.</p>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Potassium supplementation (Option A):</strong> While correcting hypokalemia can mitigate chronic toxicity, acute severe overdose often presents with hyperkalemia and requires antidotal therapy rather than further K<sup>+</sup>.</p>\r\n<p><strong>Propranolol (Option B):</strong> A nonselective &beta;-blocker that may worsen bradyarrhythmias and does not address the underlying digitalis excess.</p>\r\n<p><strong>Atropine (Option C):</strong> Temporarily increases AV nodal conduction in bradycardia but does not remove digoxin or correct its direct myocardial effects, and is insufficient in severe toxicity.</p>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/20240308c329a111-2b85-422f-bfe9-6c722649ba56.jpg\">\r\n",
      "correct_choice_id": 224,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 24,
      "choices": [
        {
          "id": 231,
          "text": "<p><span style=\"font-size:12.0pt;\">Amiodarone </span></p>"
        },
        {
          "id": 232,
          "text": "<p><span style=\"font-size:12.0pt;\">Flecainide </span></p>"
        },
        {
          "id": 233,
          "text": "<p><span style=\"font-size:12.0pt;\">Metoprolol </span></p>"
        },
        {
          "id": 234,
          "text": "<p><span style=\"font-size:12.0pt;\">Continue observation</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Mr. Agrawal underwent tPA administration for STEMI 2 hours previously. He had an excellent response with the resolution of his ST-elevation. However, you note a wide complex ventricular rhythm with a rate of 75 bpm. Mr. Agrawal feels well. The next most appropriate step?</span></p>",
      "unique_key": "DT1179777",
      "question_audio": null,
      "question_video": null,
      "map_id": 1179777,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>This rhythm is an <strong>accelerated idioventricular rhythm</strong>, a benign reperfusion arrhythmia commonly seen after successful thrombolysis or PCI.</p>\r\n<p>It arises from enhanced automaticity of ventricular Purkinje fibres with a rate between the intrinsic ventricular escape rhythm and sinus rate, reflecting restored coronary perfusion.</p>\r\n<p>No antiarrhythmic therapy is indicated, as accelerated idioventricular rhythm resolves spontaneously and treatment can provoke more dangerous arrhythmias.</p>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Amiodarone (Option A):</strong> Indicated for sustained ventricular tachycardia or fibrillation, not for benign reperfusion arrhythmias, and risks unnecessary toxicity.</p>\r\n<p><strong>Flecainide (Option B):</strong> A Class I agent contraindicated post-MI due to increased mortality risk and proarrhythmic potential.</p>\r\n<p><strong>Metoprolol (Option C):</strong> A &beta;-blocker useful for SVT or VT rate control, but unnecessary here and may depress sinus node function.</p>",
      "correct_choice_id": 234,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 25,
      "choices": [
        {
          "id": 241,
          "text": "<p><span style=\"font-size:12.0pt;\">Atropine</span></p>"
        },
        {
          "id": 242,
          "text": "<p><span style=\"font-size:12.0pt;\">Follow-up after 1 week. Avoid cricket for a week</span></p>"
        },
        {
          "id": 243,
          "text": "<p><span style=\"font-size:12.0pt;\">No further follow-up</span></p>"
        },
        {
          "id": 244,
          "text": "<p><span style=\"font-size:12.0pt;\">He should undergo a treadmill stress ECG to determine the presence of chronotropic competence.</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Mr. Kohli is a 26-year-old cricketer who comes to you for a regular check-up. On your assessment, you note a resting heart rate of 45 bpm with an occasional pause of up to 2 seconds. His blood pressure is 110/70 mmHg. He feels well and reports no syncopal or presyncopal episodes at rest or during exercise. ECG is normal. Which of the following would be the next step?</span></p>",
      "unique_key": "DT1179780",
      "question_audio": null,
      "question_video": null,
      "map_id": 1179780,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>In highly trained athletes, increased vagal tone commonly produces resting sinus bradycardia and brief sinus pauses (&le;3 seconds) that are physiologic and asymptomatic.</p>\r\n<p>Normal ECG and absence of symptoms or exercise intolerance confirm this benign adaptation-no evidence of intrinsic conduction disease.</p>\r\n<p>Reassurance without intervention avoids unnecessary tests and maintains athletic activity.</p>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Atropine (Option A):</strong> Unnecessary in physiologic bradycardia and may provoke inappropriate tachycardia.</p>\r\n<p><strong>Follow-up and activity restriction (Option B):</strong> No indication to limit sports or repeat ECG in an asymptomatic athlete with normal findings.</p>\r\n<p><strong>Treadmill stress ECG (Option D): </strong>Indicated only if symptoms or ECG abnormalities suggest chronotropic incompetence, not in this asymptomatic context.</p>\r\n",
      "correct_choice_id": 243,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 26,
      "choices": [
        {
          "id": 251,
          "text": "<p><span style=\"font-size:12.0pt;\">Adenosine</span></p>"
        },
        {
          "id": 252,
          "text": "<p><span style=\"font-size:12.0pt;\">Digoxin </span></p>"
        },
        {
          "id": 253,
          "text": "<p><span style=\"font-size:12.0pt;\">Metoprolol </span></p>"
        },
        {
          "id": 254,
          "text": "<p><span style=\"font-size:12.0pt;\">Pain control and IV hydration</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 72-year-old man with a history of COPD and osteoporosis presents after a fall. On examination, there is tenderness to palpation over the left hip, and his leg is shortened and externally rotated. His mucous membranes are dry. Blood pressure is 160/80 mmHg and heart rate is 130 bpm. ECG is shown. What is the most appropriate first step for her tachycardia ?<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/20240308bcf5bbbd-c12b-4006-9204-209bab8c5719.jpg\"></span></p>",
      "unique_key": "DT1179791",
      "question_audio": null,
      "question_video": null,
      "map_id": 1179791,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>The ECG and clinical context (COPD, acute dehydration, and fall) are diagnostic of <strong>multifocal atrial tachycardia (MAT)</strong>, arising from multiple ectopic atrial foci, not a reentrant circuit.</p>\r\n<p>Because MAT is <strong>not</strong> due to a reentry phenomenon, interventions like electrical cardioversion, which are effective for reentrant arrhythmias, do <strong>not</strong> terminate MAT. MAT in acute illness responds poorly to antiarrhythmic drugs; the cornerstone of therapy is <strong>treating underlying triggers</strong> such as pain, hypoxia, and dehydration to restore normal atrial automaticity.</p>\r\n<p><strong>IV fluids</strong> to correct volume depletion and <strong>adequate analgesia</strong> to relieve pain, reduce sympathetic drive and atrial irritability, leading to resolution of MAT without drug toxicity.</p>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Adenosine (Option A):</strong> Blocks AV nodal conduction briefly but does not affect multiple atrial foci and thus fails to terminate MAT.</p>\r\n<p><strong>Digoxin (Option B):</strong> Slows AV conduction but does not address the ectopic atrial activity driving MAT and risks toxicity in hypovolemic states.</p>\r\n<p><strong>Metoprolol (Option C):</strong> May reduce ventricular response but risks bronchospasm in COPD and again does not treat the precipitating factors of MAT.</p>",
      "correct_choice_id": 254,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 27,
      "choices": [
        {
          "id": 261,
          "text": "<p><span style=\"font-size:12.0pt;\">Increase sinus rate and maintain 2:1 AV block</span></p>"
        },
        {
          "id": 262,
          "text": "<p><span style=\"font-size:12.0pt;\">Increase sinus rate and improve heart block to 1:1 conduction</span></p>"
        },
        {
          "id": 263,
          "text": "<p><span style=\"font-size:12.0pt;\">No change in sinus rate and worsening heart block to >2:1</span></p>"
        },
        {
          "id": 264,
          "text": "<p><span style=\"font-size:12.0pt;\">No change</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 68-year-old woman referred to you for an ECG showing 2:1 second-degree AV block. If you administer atropine intravenously to the patient, you would expect which of the following to occur?</span></p>",
      "unique_key": "DT1179792",
      "question_audio": null,
      "question_video": null,
      "map_id": 1179792,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>A 2:1 block may be either nodal (Mobitz I) or infranodal (Mobitz II). In the <strong>infranodal</strong> block-below the AV node-anticholinergic agents like atropine have <strong>little to no effect</strong> on conduction or sinus rate.</p>\r\n<p>Atropine acts by reducing vagal tone at the AV node and increasing SA nodal phase-4 slope; when the block is distal, these effects do not alter ventricular conduction or heart rate.</p>\r\n<p>Lack of response to atropine in a 2:1 block helps distinguish <strong>Mobitz II</strong> (infranodal) from Mobitz I (nodal), guiding prognosis and management.</p>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Option A:</strong> &uarr; sinus rate with persistent 2:1 block suggests nodal block without conduction improvement; atropine would speed sinus but still improve AV nodal conduction in Mobitz I.</p>\r\n<p><strong>Option B:</strong> &uarr; sinus rate with conversion to 1:1 conduction indicates a nodal (Mobitz I) mechanism responsive to vagolysis-does not occur in infranodal block.</p>\r\n<p><strong>Option C:</strong> No change in rate with worsened block implies atrial rate constant and more dropped beats; atropine should raise sinus rate if SA node is responsive, so block would not worsen without rate change.</p>",
      "correct_choice_id": 264,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 28,
      "choices": [
        {
          "id": 271,
          "text": "<p><span style=\"font-size:12.0pt;\">Digoxin</span></p>"
        },
        {
          "id": 272,
          "text": "<p><span style=\"font-size:12.0pt;\">Metoprolol</span></p>"
        },
        {
          "id": 273,
          "text": "<p><span style=\"font-size:12.0pt;\">DC cardioversion</span></p>"
        },
        {
          "id": 274,
          "text": "<p><span style=\"font-size:12.0pt;\">Amiodarone</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 76-year-old man presents with 5 days of not feeling well. He has a history of nonischemic cardiomyopathy and hypertension. Blood pressure is 110/78 mmHg, and his heart rate is 150 bpm. His jugular veins are not distended, and his lungs are clear. His ECG is shown. What would be the appropriate next step?<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/20240308ee6c03e6-d9c9-46ad-aaa5-b6c9c6285818.jpg\"></span></p>",
      "unique_key": "DT1179793",
      "question_audio": null,
      "question_video": null,
      "map_id": 1179793,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>This ECG shows atrial flutter, with 2:1 conduction and the typical atrial rate of 300 bpm and ventricular rate of 150 bpm. The saw-tooth baseline pattern, best appreciated in the inferior leads, is a clue that this is <strong>atrial flutter</strong>. The appropriate next step should be to administer 5 mg of <strong>IV metoprolol, which brings his heart rate down.</strong></p>\r\n<p>However, given that the patient's symptoms have been ongoing for &gt;48 hours, he is at risk for development of an atrial thrombus (similar to that in atrial fibrillation) and thus requires systemic anticoagulation before achievement of sinus rhythm. He will also likely require a transesophageal echocardiogram to ensure that no clot exists prior to ablation or cardioversion.</p>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Digoxin (Option A):</strong> Provides modest rate control but is too slow in onset for acute rate reduction and ineffective at controlling high-rate atrial flutter alone.</p>\r\n<p><strong>DC cardioversion (Option C):</strong> Reserved for unstable patients or after anticoagulation in flutter &gt;48 hours; immediate cardioversion without anticoagulation poses thromboembolic risk.</p>\r\n<p><strong>Amiodarone (Option D):</strong> A rhythm-control agent with slow onset and limited efficacy for acute rate reduction in atrial flutter; not first-line for rate control.</p>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/20240308d44faf48-8f76-4230-809e-b4a6f25babc3.jpg\">\r\n",
      "correct_choice_id": 272,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 29,
      "choices": [
        {
          "id": 281,
          "text": "<p><span style=\"font-size:12.0pt;\">ACEIs</span></p>"
        },
        {
          "id": 282,
          "text": "<p><span style=\"font-size:12.0pt;\">ARBs</span></p>"
        },
        {
          "id": 283,
          "text": "<p><span style=\"font-size:12.0pt;\">Sildenafil</span></p>"
        },
        {
          "id": 284,
          "text": "<p><span style=\"font-size:12.0pt;\">None of the above</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following has convincingly demonstrated mortality reduction for patients with HFpEF?</span></p>",
      "unique_key": "DT1179794",
      "question_audio": null,
      "question_video": null,
      "map_id": 1179794,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<ul>\r\n<li>Multiple large randomised trials of <strong>ACE inhibitors</strong> (e.g., PEP-CHF with perindopril) and <strong>ARBs</strong> (I-PRESERVE with irbesartan; CHARM-Preserved with candesartan; TOPCAT with spironolactone, an aldosterone antagonist) in HFpEF <strong>failed to show a significant reduction in all-cause mortality</strong>. While some showed modest reductions in hospitalisations, none convincingly improved survival.</li>\r\n<li>The <strong>RELAX</strong> trial of <strong>sildenafil</strong> in HFpEF improved exercise capacity in a subset of patients but did <strong>not</strong> demonstrate a mortality benefit in longer-term follow-up.</li>\r\n<li>Pathophysiologic heterogeneity in HFpEF (diastolic dysfunction, comorbidities like hypertension, obesity, diabetes, fibrosis) likely underlies the lack of a \"one-size-fits-all\" therapeutic impact on survival.</li>\r\n<li>Current guidelines for HFpEF emphasise <strong>symptom management</strong> (diuretics for congestion), <strong>strict blood pressure control</strong>, and treatment of comorbid conditions (e.g., atrial fibrillation, ischemia) rather than reliance on agents proven to reduce mortality in HFrEF.</li>\r\n</ul>",
      "correct_choice_id": 284,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 30,
      "choices": [
        {
          "id": 291,
          "text": "<p><span style=\"font-size:12.0pt;\">1+2 +5 +6</span></p>"
        },
        {
          "id": 292,
          "text": "<p><span style=\"font-size:12.0pt;\">5+7</span></p>"
        },
        {
          "id": 293,
          "text": "<p><span style=\"font-size:12.0pt;\">4+ 5+ 6</span></p>"
        },
        {
          "id": 294,
          "text": "<p><span style=\"font-size:12.0pt;\">1+ 4+ 5+ 6 + 7</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 68-year-old man with a history of myocardial infarction and congestive heart failure is comfortable at rest. However, when walking to his car, he develops dyspnea, fatigue, and sometimes palpitations. He must rest for several minutes before these symptoms resolve. What are the current treatment guidelines for the patient?<br>1. Beta blocker<br>2.ACEIs<br>3. ARB <br>4. ARNI<br> 5. Furosemide <br>6. Spironolactone <br>7. Dobutamine <br>8. Milrinone</span></p>",
      "unique_key": "DT1179795",
      "question_audio": null,
      "question_video": null,
      "map_id": 1179795,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p><strong>ARNI (sacubitril/valsartan)</strong> is now preferred over ACE inhibitors or ARBs in symptomatic HFrEF (Stage C) to reduce morbidity and mortality by augmenting natriuretic peptides and blocking angiotensin II.</p>\r\n<p><strong>Loop diuretics (furosemide)</strong> are indicated for symptomatic relief of congestion (dyspnea, fatigue) by reducing preload.</p>\r\n<p><strong>Mineralocorticoid receptor antagonists (spironolactone)</strong> further improve survival and reduce hospitalisations in NYHA class II-IV HFrEF by antagonising aldosterone's fibrotic and sodium-retaining effects.</p>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/20240308741f5619-f0ba-4557-94ed-51df5d679b8f.jpg\">\r\n<p>The AHA classification system categorizes patients according to the stage of disease based on an objective assessment of clinical features and diagnostic findings.</p>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/20240308b0b24a5f-03a2-4499-a57b-be51f630d492.jpg\">",
      "correct_choice_id": 293,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 31,
      "choices": [
        {
          "id": 301,
          "text": "<p><span style=\"font-size:12.0pt;\">Beta-blockers</span></p>"
        },
        {
          "id": 302,
          "text": "<p><span style=\"font-size:12.0pt;\">Spironolactone</span></p>"
        },
        {
          "id": 303,
          "text": "<p><span style=\"font-size:12.0pt;\">Milrinone</span></p>"
        },
        {
          "id": 304,
          "text": "<p><span style=\"font-size:12.0pt;\">ACEIs</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 72-year-old woman with chemotherapy-related cardiomyopathy now has an ejection fraction of 15%. She has been hospitalised two times in the last 6 months with acute decompensated heart failure. She is currently NYHA class IV regarding symptoms. What drugs can be used continuously to support quality of life as a bridge therapy while waiting for a transplant?</span></p>",
      "unique_key": "DT1179796",
      "question_audio": null,
      "question_video": null,
      "map_id": 1179796,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<ul>\r\n<li>In <strong>Stage D heart failure </strong>(refractory to standard therapies and awaiting transplant), inotropic support with a PDE-3 inhibitor like <strong>milrinone provides symptomatic relief by increasing cardiac contractility and reducing afterload.</strong></li>\r\n<li>Milrinone raises intracellular cAMP in myocardium and vascular smooth muscle, improving stroke volume and producing vasodilation to lower filling pressures.</li>\r\n<li>Although continuous inotrope infusion can improve hemodynamics and quality of life as a bridge or palliative measure, it has not been shown to improve long-term survival and is reserved for end-stage patients awaiting advanced therapies.</li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/20240308af771cee-e1b8-4171-8027-62ac9086a3e1.jpg\">\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Beta-blockers (Option A):</strong> Cornerstone of chronic HFrEF management but contraindicated in acute decompensation and Stage D where rapid inotropic support is needed.</p>\r\n<p><strong>Spironolactone (Option B):</strong> Provides mortality benefit in Stage C but lacks direct positive inotropic action and is insufficient for acute low-output support.</p>\r\n<p><strong>ACE inhibitors (Option D):</strong> Improve remodeling and survival in earlier stages but do not provide the immediate increase in contractility required in refractory Stage D HF.</p>",
      "correct_choice_id": 303,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 32,
      "choices": [
        {
          "id": 311,
          "text": "<p><span style=\"font-size:12.0pt;\">Serum electrolyte</span></p>"
        },
        {
          "id": 312,
          "text": "<p><span style=\"font-size:12.0pt;\">ECG</span></p>"
        },
        {
          "id": 313,
          "text": "<p><span style=\"font-size:12.0pt;\">Thyroid function test</span></p>"
        },
        {
          "id": 314,
          "text": "<p><span style=\"font-size:12.0pt;\">Anti-histone antibody</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 56-year-old woman presents with complaints of feeling tired. She also has diarrhoea and weight loss. She also feels very anxious and nervous. She is being treated for ventricular arrhythmia. Which of the following is the next step in the management?</span></p>",
      "unique_key": "DT1179797",
      "question_audio": null,
      "question_video": null,
      "map_id": 1179797,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>Amiodarone contains a high iodine load and disrupts thyroid function; clinical syndromes include <strong>Type I</strong> (iodine induced hyperthyroidism from increased hormone synthesis) and <strong>Type II</strong> (destructive thyroiditis eventually leading to hypothyroidism).</li>\n<li>Her symptoms (weight loss, diarrhea, and anxiety) are characteristic of amiodarone-induced hyperthyroidism (Type I), but laboratory confirmation with TSH and free T4 is essential to differentiate and guide therapy.</li>\n<li>Early thyroid testing prevents misdiagnosis and directs management, whether thionamides for hyperthyroidism or thyroid hormone replacement for hypothyroidism, without delay.</li>\n</ul>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/V2NEETPGMCQ/20240319bf43b1bc-0215-4934-9df2-fba3fe3e02f2.jpg\"><br>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/202403082365f9b9-50d7-4866-989f-fc880c1e4c04.jpg\">\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Serum electrolyte measurement (Option A):</strong> Appropriate for suspected digitalis or diuretic toxicity but not for systemic thyroid effects.</p>\n<p><strong>ECG (Option B):</strong> May show conduction changes from amiodarone, but cannot diagnose thyroid dysfunction driving her systemic symptoms.</p>\n<p><strong>Anti-histone antibody assay (Option D):</strong> Used for drug-induced lupus (e.g., procainamide), irrelevant to amiodarone's thyroid effects.</p>",
      "correct_choice_id": 313,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 33,
      "choices": [
        {
          "id": 321,
          "text": "<p><span style=\"font-size:12.0pt;\">Ethosuximide</span></p>"
        },
        {
          "id": 322,
          "text": "<p><span style=\"font-size:12.0pt;\">Oral contraceptives</span></p>"
        },
        {
          "id": 323,
          "text": "<p><span style=\"font-size:12.0pt;\">Phenytoin</span></p>"
        },
        {
          "id": 324,
          "text": "<p><span style=\"font-size:12.0pt;\">Procainamide</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 28-year-old woman complains of fever, fatigue, weight loss, arthralgia, and transient patchy alopecia during the last 3 months. She is on treatment for a cardiovascular disease. Antinuclear antibody testing is positive. Presently, her hematocrit is 33% and creatinine is 1.2 mg/dL. The most likely cause?</span></p>",
      "unique_key": "DT1179798",
      "question_audio": null,
      "question_video": null,
      "map_id": 1179798,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>Several drugs can cause a syndrome resembling systemic lupus erythematosus (SLE). The syndrome is most common with procainamide, which induces the presence of antinuclear antibodies in up to 75% of individuals within a few months. There is a genetic predisposition to drug-induced lupus determined by drug acetylation rates.</p>\n<ul>\n<li>Genetic susceptibility\n<ul>\n<li>Decreased acetyltransferase activity resulting in slow acetylation of drugs</li>\n<li>Presence of HLA-DR2, HLA-DR3, HLA-DR4, or an unexpressed C4 complement allele</li>\n</ul>\n</li>\n<li>Common drug triggers (<strong><em><u>SHyPS</u></em></strong>)\n<ul>\n<li>Sulfa drugs</li>\n<li>Certain nonsulfa drugs, e.g., procainamide, hydralazine, isoniazid, methyldopa, minocycline, phenytoin, TNF-&alpha; inhibitors</li>\n</ul>\n</li>\n</ul>\n<p>Typical symptoms include systemic complaints and arthralgias. The initial therapeutic approach is the withdrawal of the offending drug.</p>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Ethosuximide (Option A):</strong> Rare, anecdotal reports exist, but it is not a well-established cause of drug-induced lupus.</p>\n<p><strong>Oral contraceptives (Option B):</strong> Do not reliably induce lupus and are rarely implicated in ANA positivity or clinical lupus syndromes.</p>\n<p><strong>Phenytoin (Option C):</strong> Can cause hypersensitivity and drug reactions, but has no strong association with lupus-like syndromes.</p>",
      "correct_choice_id": 324,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 34,
      "choices": [
        {
          "id": 331,
          "text": "<p><span style=\"font-size:12.0pt;\">Verapamil</span></p>"
        },
        {
          "id": 332,
          "text": "<p><span style=\"font-size:12.0pt;\">Amiodarone</span></p>"
        },
        {
          "id": 333,
          "text": "<p><span style=\"font-size:12.0pt;\">Furosemide</span></p>"
        },
        {
          "id": 334,
          "text": "<p><span style=\"font-size:12.0pt;\">Hydralazine</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 68-year-old man is on metoprolol, ACEIs and Chlorthalidone for his cardiac condition. Which of the following drugs should be avoided to prevent AV block?</span></p>",
      "unique_key": "DT1179799",
      "question_audio": null,
      "question_video": null,
      "map_id": 1179799,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>Verapamil is a non-dihydropyridine calcium-channel blocker that slows AV nodal conduction.</p>\r\n<p>When combined with a &beta;-blocker like metoprolol, the additive AV block and sinus-node depression can lead to significant bradycardia or high-degree AV block.</p>\r\n<p>Verapamil also has negative inotropic effects, potentially worsening heart failure in this patient.</p>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Amiodarone (Option B):</strong> Although it affects conduction, it is not typically combined with &beta;-blockers to produce AV block and is used cautiously for arrhythmias rather than for hypertension or fluid management.</p>\r\n<p><strong>Furosemide (Option C):</strong> A loop diuretic with no direct effects on AV nodal conduction.</p>\r\n<p><strong>Hydralazine (Option D):</strong> A direct arteriolar vasodilator that does not impact AV nodal conduction.</p>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<p>To avoid drug-induced AV block, remember the \"ABCD\" agents that slow AV nodal conduction:</p>\r\n<ul>\r\n<li><strong>A</strong>denosine</li>\r\n<li><strong>B</strong>eta-blockers</li>\r\n<li><strong>C</strong>alcium-channel blockers (non-DHP: verapamil, diltiazem)</li>\r\n<li><strong>D</strong>igoxin</li>\r\n</ul>",
      "correct_choice_id": 331,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 35,
      "choices": [
        {
          "id": 341,
          "text": "<p><span style=\"font-size:12.0pt;\">1-B 2-C 3-A 4-D</span></p>"
        },
        {
          "id": 342,
          "text": "<p><span style=\"font-size:12.0pt;\">1-B 2-D 3-A 4-C</span></p>"
        },
        {
          "id": 343,
          "text": "<p><span style=\"font-size:12.0pt;\">1-C 2-D 3-A 4-B</span></p>"
        },
        {
          "id": 344,
          "text": "<p><span style=\"font-size:12.0pt;\">1-D 2-A 3-B 4-C</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Match the following drugs with their side effects.<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/2024030821ff3a94-201f-43a6-9fa9-eb175600081b.jpg\"></span></p>",
      "unique_key": "DT1179800",
      "question_audio": null,
      "question_video": null,
      "map_id": 1179800,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p><strong>Disopyramide &rarr; B:</strong> As a Class IA antiarrhythmic with strong anticholinergic properties, disopyramide commonly causes dry mouth, hyperthermia, and mydriasis.</p>\r\n<p><strong>Lidocaine &rarr; D:</strong> Lidocaine toxicity manifests predominantly as central nervous system effects (nystagmus, confusion, and seizures), especially with high doses or reduced clearance.</p>\r\n<p><strong>Amiodarone &rarr; A:</strong> Chronic amiodarone therapy can induce peripheral neuropathy, along with pulmonary fibrosis and thyroid dysfunction, due to tissue accumulation of iodine-rich drugs.</p>\r\n<p><strong>MgSO<sup>4</sup> &rarr; C: </strong>In overdose or rapid infusion, magnesium sulfate causes neuromuscular blockade leading to respiratory depression and hyporeflexia.</p>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/202403089dadd17e-7960-47d8-b652-a301f5763434.jpg\"><br>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/2024030894702cc8-5218-4f14-bf5d-9aad98230b67.jpg\">",
      "correct_choice_id": 342,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 36,
      "choices": [
        {
          "id": 351,
          "text": "<p><span style=\"font-size:12.0pt;\">A 12-year-old with congenital LQTS = Magnesium sulphate</span></p>"
        },
        {
          "id": 352,
          "text": "<p><span style=\"font-size:12.0pt;\">A 45-year-old with supraventricular arrhythmia = Verapamil</span></p>"
        },
        {
          "id": 353,
          "text": "<p><span style=\"font-size:12.0pt;\">A 67-year-old on digoxin with supraventricular arrhythmia = Propranolol</span></p>"
        },
        {
          "id": 354,
          "text": "<p><span style=\"font-size:12.0pt;\">A 56-year-old with ventricular arrhythmia due after MI = lidocaine</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Identify the incorrect choice regarding the choice of an anti-arrhythmic.</span></p>",
      "unique_key": "DT1179801",
      "question_audio": null,
      "question_video": null,
      "map_id": 1179801,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation for answer:</strong></p>\r\n<p>In congenital long QT syndrome, the cornerstone of therapy is chronic nonselective &beta;-blockade (e.g., propranolol or nadolol) to blunt sympathetic triggers and prevent torsades; magnesium sulfate is reserved for <strong>acute</strong> termination of torsades de pointes, not for long-term management of the channelopathy.</p>\r\n<p>Magnesium stabilises cardiomyocyte membranes and suppresses early afterdepolarizations in drug- or electrolyte-induced torsades, but it does not correct the underlying repolarisation defect in congenital LQTS.</p>\r\n<p>Thus, prescribing magnesium sulfate as the initial antiarrhythmic in congenital LQTS is inappropriate.</p>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Verapamil (Option B):</strong> A nondihydropyridine CCB effective for rate control in reentrant SVTs by slowing AV nodal conduction.</p>\r\n<p><strong>Propranolol (Option C):</strong> A &beta;-blocker ideal for slowing ventricular rate in digoxin-induced supraventricular arrhythmias and protective against digoxin's proarrhythmic effects.</p>\r\n<p><strong>Lidocaine (Option D):</strong> A Class IB agent first-line for acute ventricular tachycardia post-myocardial infarction, reducing ectopic automaticity in ischemic tissue.</p>",
      "correct_choice_id": 351,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 37,
      "choices": [
        {
          "id": 361,
          "text": "<p><span style=\"font-size:12.0pt;\">Metoprolol </span></p>"
        },
        {
          "id": 362,
          "text": "<p><span style=\"font-size:12.0pt;\">Quinidine</span></p>"
        },
        {
          "id": 363,
          "text": "<p><span style=\"font-size:12.0pt;\">Carotid sinus massage</span></p>"
        },
        {
          "id": 364,
          "text": "<p><span style=\"font-size:12.0pt;\">DC cardioversion using 100 J</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 40-year-old woman presents with a sudden onset of palpitations. Her heart rate is 170 bpm and blood pressure is 100/60 mmHg with normal oxygen saturation. On examination, she has a 'frog sign' in her neck. ECG shows a narrow complex tachycardia without identifiable P waves. Which of the following is the most appropriate first step?</span></p>",
      "unique_key": "DT1179802",
      "question_audio": null,
      "question_video": null,
      "map_id": 1179802,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>This patient has classical findings of AVNRT. The so-called frog sign (prominent venous pulsations in the neck due to cannon A waves seen in AV dissociation) on examination is frequently present and suggests simultaneous atrial and ventricular contraction.</p>\r\n<p>First-line therapy for these reentrant narrow complex tachyarrhythmias is carotid sinus massage to increase vagal tone. Often, this is all that is required to return the patient to sinus rhythm. If that is not successful, intravenous (IV) adenosine 6&ndash;12 mg may be attempted. If adenosine fails, IV &beta;-blockers or calcium channel blockers may be used (diltiazem or verapamil). Finally, in hemodynamically compromised patients or those who have failed to respond to previous measures, direct current (DC) cardioversion with 100-200 J is indicated.</p>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/202403089f4b3a83-ebaf-44c5-93b6-3f7f63dfd003.jpg\">",
      "correct_choice_id": 363,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}